Neurology Updates

Phase 2/3 DEVOTE trial reached the primary endpoint, which is improvement in the CHOP INTEND score in the 50/28 mg nusinersen regimen compared with…

Recessive RNU2-2 syndrome is a highly prevalent neurodevelopmental disorder characterized by severe developmental delay, epilepsy, and overlap with…

The aim of epilepsy treatments is to achieve greater efficacy and fewer side effects. Recent real-world evidence showed that cenobamate demonstrates…

Piet et al. propose a new paradigm: epilepsy risk and phenotype are determined by the combined effects of rare high-impact variants and the polygenic…

People with dementia often have palliative care needs as they deteriorate and this study suggests areas for assessment, in particular, hospital use,…

Delpacibart etedesiran, a monoclonal antibody–oligonucleotide conjugate, showed delivery to muscle and improvement of aberrant splicing in patients…

The glymphatic system is a brain‑wide system thought to help clear waste products from the central nervous system. It appears to work in close…

CAR‑T therapy, originally developed for oncology, is now emerging as a potential treatment modality in neuroimmunology. By engineering patients’ T…

Late-onset epilepsy patients seem to have an increased risk of developing dementia. The Ballerini et al. prospective study showed normal…

EMA has recommended granting a marketing authorisation in the European Union for Levacetylleucine for the treatment of neurological manifestations in…

This study by Kumar et al. explores the neural circuits underlying cognitive dysfunction in spinocerebellar ataxia type 2 (SCA2), an inherited…

Stiff Person Syndrome (SPS) is an autoimmune neurological disorder marked by rigidity, spasms, and heightened sensitivity to stimuli, often associated…